Log in

Company updateBusinessLine

Cipla US facility gets FDA No Action Indicated status

Positive+202 sources

GreyOak summary

Cipla Ltd's subsidiary, InvaGen Pharmaceuticals Inc, received a 'No Action Indicated' classification from the US FDA. This status follows an inspection of the New York manufacturing facility conducted between October 19 and October 22, 2026. The regulator found no objectionable conditions or regulatory violations during the visit.

What it affects

  • CiplaCIPLAPositive +20

    FDA inspection found no violations.Rolling sentiment Neutral -8

Source

Read the original at BusinessLine

More Cipla news

All Cipla news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy